Pfizer and biontech receive positive chmp opinion for conversion of comirnaty® conditional marketing authorization to full marketing authorization in the european union

New york and mainz, germany, september 16, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has recommended converting the conditional marketing authorization (cma) for comirnaty® [covid-19 vaccine (nucleoside modified)] to standard (also referred to as “full”) marketing authorization (ma) for all authorized indications and formulations. the european commission (ec) will review the chmp recommendation and is soon expected to make a final decision.
BNTX Ratings Summary
BNTX Quant Ranking